TissueGene-C
Phase 3Biologic
TissueGene-C is one of 47 biologic programs targeting Arthritis. It is currently in Phase 3.
2
Indications
7
Total Trials
0
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Simponi
Johnson & JohnsonPhase 3
Taltz
Eli LillyPhase 3
Aleve
Alnylam PharmaceuticalsPhase 3
Stelara
Johnson & JohnsonPhase 3
Ilaris
NovartisPhase 3
Bimzelx
UCBPhase 3
Kenalog
BBassett Healthcare
Phase 3
Remicade
OOrganon and Co
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Arthritis5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TissueGene-C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- KKolon Life Science